Dynavax Technologies Corp. (DVAX) Stock Price Up 4.9%
Dynavax Technologies Corp. (NASDAQ:DVAX) rose 4.9% during mid-day trading on Friday . The stock traded as high as $16.75 and last traded at $16.73, with a volume of 626,684 shares traded. The stock had previously closed at $15.95.
A number of equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Dynavax Technologies Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th. JPMorgan Chase & Co. downgraded Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $29.00 to $22.00 in a research report on Wednesday, April 27th. Royal Bank Of Canada downgraded Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and lowered their price objective for the stock from $48.00 to $17.00 in a research report on Wednesday, April 27th. Finally, Cowen and Company reiterated a “buy” rating and issued a $60.00 price objective on shares of Dynavax Technologies Corp. in a research report on Thursday, April 28th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $32.20.
The firm’s 50 day moving average price is $14.98 and its 200-day moving average price is $17.62. The stock’s market cap is $644.02 million.
Dynavax Technologies Corp. (NASDAQ:DVAX) last posted its earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by $0.07. During the same period in the previous year, the business posted ($0.80) earnings per share. The business had revenue of $2.65 million for the quarter, compared to analyst estimates of $1.58 million. The company’s revenue for the quarter was up 70.8% compared to the same quarter last year. Analysts forecast that Dynavax Technologies Corp. will post ($2.90) EPS for the current fiscal year.
In related news, CEO Eddie Gray bought 2,750 shares of the business’s stock in a transaction on Friday, May 20th. The stock was acquired at an average price of $15.57 per share, with a total value of $42,817.50. Following the transaction, the chief executive officer now owns 5,050 shares in the company, valued at approximately $78,628.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Other large investors recently bought and sold shares of the company. Swiss National Bank increased its stake in Dynavax Technologies Corp. by 5.7% in the fourth quarter. Swiss National Bank now owns 48,528 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 2,600 shares during the period. California State Teachers Retirement System increased its stake in shares of Dynavax Technologies Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,895 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 1,177 shares during the last quarter. Finally, Trexquant Investment LP increased its stake in shares of Dynavax Technologies Corp. by 14.5% in the fourth quarter. Trexquant Investment LP now owns 70,200 shares of the biopharmaceutical company’s stock worth $1,696,000 after buying an additional 8,911 shares during the last quarter.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.